Join us in Barcelona to take your
pharma business to the next level!
Meet our
Dr.Reddy’s API team at
CPHI Barcelona, 2023
24th-26th October 2023
Fira Barcelona Gran Via, Spain Booth 4C30Our Team at CPHI Barcelona 2023
-
Deepak Sapra
CEO, Pharmaceutical Services And Active Ingredients
-
Kalpesh Kumar Modi
Vice President and Region Head - Europe
-
Sumit Kumar
Vice President and Region Head - US
-
Gunjan Singh
Vice President and Head- US & Europe
-
Nirav K Shah
Vice President and Head - North Asia
-
B Vivek
Executive VP and Global Head Supply, Demand Planning and Delivery
-
Gustavo Mayrink
Vice President, Sales & Marketing – LATAM
-
Karun Gaur
Vice President - SEMEA
-
Dr. A Kalyan Chakravarthy
Vice President & Head
-
Siddhartha Deshpande
Associate Vice president - SEMEA
-
Rohan Kaushik
Associate Vice President, BD & Portfolio - North Asia
-
Dr. Rajeev Rehani Budhdev
Executive Vice President , API R&D
-
E Sreedhar
Executive VP, API Regulatory Affairs
-
Mohammad Azharuddin khan
Vice president and head - SEMEA and LATAM
Sales and marketing
About CPHI Barcelona 2023
CPHI Barcelona 2023 is an exceptional event at the heart of the pharmaceutical industry, dedicated to advancing human health and fostering global collaboration. Taking place in Barcelona, Spain, this in-person gathering will be held from October 24th to 26th, 2023, at the prestigious Fira Barcelona Gran Via.
At CPHI Barcelona, you'll have the opportunity to collaborate, expand your expertise, and get inspiration from emerginginnovations. We have the perfect pass for you and we can't wait to see you in Barcelona! Schedule your meeting with our team today!
About Dr.Reddy’s API Business
We specialise in manufacturing and supplying a wide range of APIs for generic formulation manufacturers in India and overseas. The company has a diversified portfolio of 150+ active pharmaceutical ingredients, which are used in major therapeutic areas such as gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. Our API manufacturing facilities adhere to cGMP (ICH Q7) and are inspected on a regular basis by international regulatory bodies. We have eight commercially inspected USFDA production plants, six in India and one each in Mexico and the United Kingdom.
Dr. Reddy's API business operates in a number of global markets, including the United States of America, Latin America, Europe, India, Russia, and other CIS nations.
Sustainability
Dr. Reddy's is among the top sustainable pharmaceutical companies globally. We are listed in the sustainability yearbook of S&P 2022 for the second year in a row and the Bloomberg Gender-Equality Index (GEI) for the fifth consecutive year. In addition, we were ranked ninth in the Dow Jones Sustainability Index (DJSI) 2021 among the most sustainable pharmaceutical companies in the world. In our sustainability journey, these accolades are humbling and demonstrate that we're on the right track. These awards recognize our consistent performance in the environment, social, and governance (ESG) framework. Sustainability and ESG are becoming increasingly important topics for all stakeholders, so we will strive to maintain visibility in these areas.
Our Achievement
2021
21/01/2021
Best Supply Chain Team
of the Year - Pharma- 2021
2021
11/11/2021
The winner of the Corporate
social responsibility (CSR)
Initiative of the year at Global
generics & Biosimilars Awards
2021
07/10/2021
The winner of the Best Indian
Company in the US -
Manufacturing
Sector for the year 2021
COVID-19: Prime Minister
of India Meets Pharma leaders
On October 23, 2021, Prime Minister Narendra
Modi met Indian COVID-19 vaccine manufacturers,
including Dr. Reddy's. During the meeting,
2021
21/01/2021
Best Supply Chain Team
of the Year - Pharma- 2021
2021
11/11/2021
The winner of the Corporate
social responsibility (CSR)
Initiative of the year at Global
generics & Biosimilars Awards
2021
07/10/2021
The winner of the Best Indian
Company in the US -
Manufacturing
Sector for the year 2021
COVID-19: Prime Minister
of India Meets Pharma leaders
On October 23, 2021, Prime Minister Narendra
Modi met Indian COVID-19 vaccine manufacturers,
including Dr. Reddy's. During the meeting,
Manufacturing Location
Disclaimer
No information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. Products protected under valid patents in India are not available for commercial use but would be available for Section 107A purposes.